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Objectives This study was undertaken to evaluate the efficacy and safety of rosuvastatin therapy for children with familial
hypercholesterolemia.
Background Familial hypercholesterolemia is a common inherited disorder causing markedly elevated low-density lipoprotein
cholesterol (LDL-C) levels from birth and resulting in premature atherosclerosis. In children, statins have been
shown to be effective in reducing LDL-C, restoring flow-mediated dilation, and slowing carotid intima-media
thickening. However, few children in these trials achieved current LDL-C goals.
Methods This study comprised a 12-week double-blind, randomized, placebo-controlled trial, followed by a 40-week open-
label, titration-to-goal extension phase in 177 pubertal children, ages 10 to 17 years, with familial hypercholes-
terolemia. Participants were randomly assigned to placebo or rosuvastatin 5, 10, or 20 mg once daily.
Results Compared with placebo, rosuvastatin 5, 10, and 20 mg reduced LDL-C by 38%, 45%, and 50%, respectively
(p  0.001 for each group vs. placebo). With a maximum allowed dose of 20 mg, 40% achieved the treatment
goal of 110 mg/dl during the open-label, titration-to-goal phase. Rosuvastatin was well tolerated, with no ap-
parent adverse impact on growth or development.
Conclusions In children with familial hypercholesterolemia, rosuvastatin 20 mg daily reduced LDL-C by 50%. Nonetheless,
only 40% attained the consensus LDL-C target of 110 mg/dl, reflecting these patients’ high baseline LDL-C
levels (mean, 232 mg/dl). (Pediatric Lipid-Reduction Trial of Rosuvastatin [PLUTO]; NCT00355615) (J Am Coll
Cardiol 2010;55:1121–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.042a
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oamilial hypercholesterolemia (FH) is an autosomal
ominant genetic disorder (1) characterized by markedly
levated low-density lipoprotein cholesterol (LDL-C)
evels leading to premature atherosclerosis and cardiovas-
ular events (2). Children with FH exhibit functional and
orphologic atherosclerotic arterial wall changes from a
oung age (3–5).
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Rosuvastatin Therapy for Children With FH March 16, 2010:1121–6mortality of untreated FH, cur-
rent consensus-based guidelines
recommend initiation of phar-
macologic treatment in child-
hood (8), with LDL-C treat-
ment goals of 130 mg/dl, or
110 mg/dl in patients with
other risk factors (9).
Although statins are the main-
stay of treatment for children
with FH, even the LDL-C tar-
get of 130 mg/dl is difficult to
achieve (10). Rosuvastatin effec-
tively lowers LDL-C in adults
(11), but has not been previously
tudied in children. This study investigated the efficacy and
afety of rosuvastatin in children with FH.
ethods
tudy design. The PLUTO (Pediatric Lipid-redUction
rial of rOsuvastatin [D3561C00087]) study protocol was
pproved by local institutional review boards, and written
nformed consent was obtained from participants and their
arents. The study was a multicenter (Online Appendix),
-stage trial: after a 6-week diet-only lead-in, eligible
articipants were randomly allocated (1:1:1:1 to placebo or
osuvastatin 5, 10, or 20 mg daily), stratified by center, for
Figure 1 Allocation and Disposition of Study Subjects
The flow chart details the allocation and disposition of subjects in the PLUTO stud
Abbreviations
and Acronyms
AE  adverse event
Apo  apolipoprotein
CK  creatine kinase
CVD  cardiovascular
disease
FH  familial
hypercholesterolemia
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol2 weeks, followed by a 40-week open-label, dose-titration
hase. After the double-blind phase, placebo recipients and
ubjects with LDL-C 110 mg/dl on their assigned rosu-
astatin dose began the open-label phase on rosuvastatin
mg. All others continued their rosuvastatin dose from the
ouble-blind phase. In the open-label phase, LDL-C values were
eported to investigators as well as to participants. The rosuvastatin
ose was uptitrated, at the discretion of the investigator, to a
aximum dose of 20 mg to attain the LDL-C target of
110 mg/dl.
tudy population. Patients were enrolled at 20 centers in
urope and North America, with the first patient enrolled in
uly 2006 and the trial completed in June 2008. Adolescents,
ge 10 to 17 years, were eligible if they had: 1) diagnosis of
eterozygous FH by documentation of a genetic defect or by
re-defined clinical criteria (12); 2) Tanner stage II, with
emale subjects being at least 1 year post-menarche; and 3) fasting
DL-C 190 mg/dl, or LDL-C 160 mg/dl if there was a
amily history of premature cardiovascular disease (CVD) or if
he patient had 2 other risk factors for CVD.
utcome measures. The primary outcome measure was
he percentage change from baseline in LDL-C during the
ouble-blind period for each treatment group compared with
lacebo. Secondary measures were the changes in other
ipoproteins and attainment of LDL-C goal. LDL-C was
stimated by the Friedewald equation (13). Compliance was
ssessed by pill count. Safety assessments included incidence
adverse event; SAE  serious adverse event.y. AE 
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March 16, 2010:1121–6 Rosuvastatin Therapy for Children With FHnd severity of adverse events (AEs), laboratory values (full
lood count and cell indices, albumin, total protein, liver
nzymes, bilirubin, creatine kinase [CK], blood urea nitrogen,
erum creatinine, calcium, fasting glucose, phosphorus, potas-
ium sodium, thyroid-stimulating hormone, glycosylated
emoglobin, and urinalyses including creatinine and protein),
nd growth and development. For height, weight, and body
ass index, z-scores were calculated (14); a z-score of 0
ndicates the population mean for age and sex. Pubertal
evelopment was assessed by Tanner stage.
ample size calculation and statistical analyses. The
ample size was set to achieve at least 150 evaluable patients
t the end of the double-blind period. Assuming that the
ercentage change from baseline for LDL-C has a standard
eviation of 15% and using a 2-sided alpha of 0.05, a sample
ize of 37 patients per group would have allowed 90% power to
etect a true treatment effect size of 12%. The primary efficacy
nalysis was based on the intention-to-treat population,
efined as patients who had taken at least 1 dose of study
edication. For the primary efficacy end point, analysis of
ovariance, with treatment group as an independent variable
nd baseline LDL-C as the covariate, was used to compare
ach active-dose group with placebo. For analyses of secondary
nd points, no adjustment was made for multiple comparisons.
p value 0.05 was considered statistically significant.
esults
f 222 participants screened, 177 were randomized (Fig. 1).
ne patient did not take any study medication after
Baseline Characteristics and Compliance With SDuring the Doubl -Blind Phase (All R domizedTable 1 B seline Charact ristics and CompDuring the Double-Blind Phase (All
Treatm
Placebo (n  46)
Male 24 (52)
Age, yrs
Male 13.9 1.5
Female 14.8 1.7
Caucasian 41 (89)
Tanner stage
II 8 (17)
III 8 (17)
IV 20 (44)
V 10 (22)
Height, cm 163.3 8.6
Weight, kg 58.0 13.4
BMI kg/m2, z-score 0.4 0.9
Waist circumference, cm 76.2 10.6
Blood pressure, mm Hg
Systolic 110 11
Diastolic 66 9
Overall compliance 80% 37 (80)
Values are n (%) or mean  SD. *A z-score of 0 indicates the populat
BMI  body mass index.andomization, resulting in 176 patients being included in bhe analyses. The mean (SD) age of the participants was
4.5 (1.8) years (range 10 to 17 years); 97 (55%) were male.
t baseline, demographic and clinical characteristics were
imilar in the 4 treatment groups (Table 1). Of 174 patients
ompleting the double-blind phase, 173 continued to the
pen-label phase, and 164 (95%) completed the trial.
Baseline LDL-C and other lipoprotein levels were com-
arable among treatment arms. Reductions from baseline in
DL-C during the double-blind phase were 1%, 38%, 45%,
nd 50% for placebo, rosuvastatin 5, 10, and 20 mg,
espectively (p  0.001 for all doses vs. placebo) (Table 2).
ignificant reductions, relative to placebo, were also found
or total cholesterol and apolipoprotein (Apo) B, but not
or triglycerides (Table 2). High-density lipoprotein-
holesterol (HDL-C) and ApoA-I were not significantly
ifferent from placebo.
During the double-blind phase, the LDL-C target of
110 mg/dl was achieved in no patient treated with placebo
ersus 12%, 41%, and 41% of patients treated with rosuv-
statin 5, 10, and 20 mg, respectively. In the open-label
hase, this goal was attained in 40% of participants. The
econdary goal of 130 mg/dl was reached in 68% of
ubjects during the open-label phase. At the end of the
pen-label phase, 26 participants were receiving rosuvasta-
in 5 mg, 25 were receiving rosuvastatin 10 mg, and 122
ere receiving rosuvastatin 20 mg.
Approximately 90% of subjects in the double-blind phase
nd 60% of subjects in the open-label phase maintained
80% compliance to study medication. During the double-
Treatmentnts, n  177)With Study Treatment
omized Patients, n  177)
ssignment During Double-Blind Phase
Rosuvastatin
(n  42) 10 mg (n  44) 20 mg (n  45)
(62) 25 (57) 22 (49)
.9 1.9 14.0 1.5 13.6 1.8
.4 2.0 15.2 1.2 14.8 1.6
(93) 42 (96) 43 (96)
(14) 7 (16) 9 (20)
(33) 4 (9) 5 (11)
(26) 20 (46) 20 (44)
(26) 13 (30) 11 (24)
.2 11.5 167.0 10.3 163.3 10.9
.6 13.0 60.8 13.7 59.0 12.6
.1 1.2 0.3 1.1 0.5 0.8
.7 11.2 76.3 11.1 75.8 10.8
9 11 112 11 112 14
3 8 66 6 67 8
(88) 40 (91) 40 (89)
n for age and sex.tudyPatieliance
Rand
ent A
5 mg
26
13
14
39
6
14
11
11
165
56
0
74
10
6
37lind phase, compliance was 88.7  12.4% on rosuvastatin
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Rosuvastatin Therapy for Children With FH March 16, 2010:1121–6mg, 91.8  10.1% on rosuvastatin 10 mg, 90.9  11.4%
n rosuvastatin 20 mg, and 88.4  18.5% on placebo.
During the double-blind phase, the overall frequencies of
Es were 54%, 50%, 64%, and 55%, with the most common
Es being headache (n  9, n  6, n  7, n  9),
asopharyngitis (n  5, n  3, n  7, n  7), influenza
n 4, n 2, n 2, n 0), myalgia (n 0, n 1, n 1,
 2), and nausea (n  2, n  2, n  0, n  2) in the
lacebo and rosuvastatin 5, 10, and 20 mg groups, respec-
ively. One serious AE of blurred vision occurred in the
lacebo group during the double-blind phase, and 1 patient
eceiving rosuvastatin 20 mg had a vesicular rash during the
pen-label phase that progressed to cellulitis.
There were no hepatic, skeletal muscle, or renal AEs that
ed to permanent treatment discontinuation. Changes in
spartate aminotransferase, alanine aminotransferase, and
Lipid Values and Percent Change From BaselineRan omiz d, Placebo-Controlled Phase (Int ntioTable 2 Lipid Values and Percent Ch nge FrRandomized, Placebo-Controlled Ph
Placebo (n  46) 5 m
Lipids, mg/dl
TC
Baseline 293 (50) 30
Week 12 293 (54) 20
% change 0
p value
LDL-C
Baseline 229 (43) 23
Week 12 227 (49) 14
% change 1
p value
HDL-C
Baseline 45 (11) 4
Week 12 48 (10) 4
% change 7
p value
TG*
Baseline 82 (57–124) 8
Week 12 78 (60–107) 6
% change 7
p value
Apolipoproteins, g/l
ApoB
Baseline 1.4 (0.3) 1
Week 12 1.4 (0.3) 1
% change 2
p value
ApoA-I
Baseline 1.3 (0.2) 1
Week 12 1.3 (0.2) 1
% change 4
p value
Data are expressed as mean (SD); changes are least squares mean %
(interquartile range); changes are median % change from baseline ass
analysis of covariance with treatment group and baseline level as cov
ApoA  apolipoprotein A; ApoB  apolipoprotein B; HDL-C  high
TC  total cholesterol.K values during the double-blind phase were similar among groups (Table 3). Transaminase elevation 3 times
he upper limit of normal was observed in 3 patients
1 receiving rosuvastatin 10 mg, 2 receiving rosuvastatin
0 mg) during the double-blind phase. In the open-label
hase, 1 patient experienced transaminase elevation 3
imes the upper limit of normal. For all patients, transami-
ases normalized while continuing treatment or remained
ormal after resumption of rosuvastatin therapy.
Creatine kinase elevation 10 times the upper limit of
ormal was observed in 4 patients during the double-blind
hase (2 each on rosuvastatin 10 and 20 mg) and 4 during
he open-label phase. Myalgia was reported by 4 patients
3%) taking rosuvastatin during the double-blind phase and
(3%) during the open-label phase. Myopathy attributed to
hysical activity was reported in 2 patients (1 each on
osuvastatin 10 and 20 mg). For all patients, symptoms
ng Double-Blind,reat Population, n  176)aseline During Double-Blind,
Intention-to-Treat Population, n  176)
Rosuvastatin
 42) 10 mg (n  44) 20 mg (n  44)
297 (49) 302 (50)
195 (44) 183 (36)
34 39
01 0.001 0.001
229 (45) 237 (48)
128 (40) 117 (33)
45 50
01 0.001 0.001
49 (10) 47 (13)
54 (11) 50 (13)
10 9
0.2 0.5
100) 81 (53–105) 81 (59–107)
83) 61 (49–77) 64 (46–92)
15 16
0.1 0.1
) 1.4 (0.2) 1.5 (0.3)
) 0.9 (0.3) 0.9 (0.2)
38 41
01 0.001 0.001
) 1.4 (0.3) 1.3 (0.3)
) 1.5 (0.2) 1.4 (0.2)
4 4
0.3 0.6
from baseline. *For triglycerides (TG), data are expressed as median
y the Kruskal-Wallis Test. Differences from placebo were assessed by
.
lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol;Durin-to-Tom B
ase (
g (n
0 (60)
7 (37)
30
0.0
8 (55)
3 (31)
38
0.0
6 (12)
8 (12)
4
0.4
0 (55–
1 (48–
13
0.8
.5 (0.4
.0 (0.2
32
0.0
.3 (0.2
.3 (0.2
2
0.7
change
essed b
ariatesnd/or CK elevation normalized while continuing treatment
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March 16, 2010:1121–6 Rosuvastatin Therapy for Children With FHr remained normal after resumption of rosuvastatin ther-
py. No clinically meaningful renal abnormalities were
bserved.
Height, weight, and sexual development progressed nor-
ally (data not shown).
iscussion
his study is the first to our knowledge to evaluate the
fficacy and safety of rosuvastatin in a pediatric population.
osuvastatin 5, 10, and 20 mg once daily lowered LDL-C
y 38%, 45%, and 50%, respectively, and 40% of participants
eached an LDL-C goal of 110 mg/dl. No untoward
afety effects were observed during this 1-year trial.
The LDL-C reductions observed with these rosuvastatin
oses in this study are consistent with those seen in adults
11,15), and at the 20-mg dose, are the largest reported in
H children to date with any statin. Pediatric studies with
ther statins reported LDL-C reductions ranging from 24%
or pravastatin 40 mg to as high as 40% for atorvastatin 10
o 20 mg (7,10). For this trial, the maximum statin dose
valuated was the second-highest dose approved for adults,
onsistent with other statin trials in children with FH
4,7,10,16).
In addition to LDL-C–lowering efficacy, this study also
ssessed the ability of rosuvastatin to reach the recently
roposed LDL-C treatment goal of 110 mg/dl recom-
ended for adolescents with FH and other risk factors such
s a family history of premature CVD (9), which was
pplicable to 89% of our participants. Despite the increased
DL-C–lowering achieved with rosuvastatin 20 mg, 60% of
atients still did not achieve this goal, reflecting the diffi-
Baseline Values and Change at End of Double-BTransamin ses, CK, GFR, and Uri e P:C (Saf tyTable 3 Ba eline Values nd Change at EndTransaminases, CK, GFR, and Urine
Placebo (n  46)
Median (Q1, Q3)
AST, U/l
Baseline 19.5 (17, 23)
Change at week 12 0 (2, 3)
ALT, U/l
Baseline 14 (12, 17)
Change at week 12 0.5 (1, 3)
CK, g/l
Baseline 106 (72, 138)
Change at week 12 1.5 (25, 52)
Mean (SD)
GFR, ml/min/1.73 m2
Baseline 147 (27)
Change at week 12 3.9 (12)
Urine P:C, mg/mg
Baseline 0.07 (0.05)
Change at week 12 0.01 (0.03)
ALT  alanine aminotransferase; AST  aspartate aminotransferas
creatinine ratio; Q1  first quartile; Q3  third quartile.ulty in meeting this target in many FH patients. The Neason not all patients who did not achieve the treatment
oal were receiving maximum rosuvastatin therapy is un-
nown, because the titration to the maximal allowed dose
as at the discretion of the investigator and the rationale not
o do so was not required or documented. A less stringent
reatment goal of 130 mg/dl was achieved in 68% of the
articipants. In adults with FH, 22% and 37% achieved this
oal with rosuvastatin 20 and 40 mg, respectively (15).
A consistent increase in HDL-C is well documented in
dults on rosuvastatin treatment (11), and prior placebo-
ontrolled trials in children with other statins have shown
ncreases in HDL-C (7,10,17). In contrast, the effect of
osuvastatin on HDL-C and ApoA-I in this study was
odest and not significant when compared with placebo,
ossibly due to a 7% increase in HDL-C in the placebo arm.
hile methodologic drift, specifically calibration, could
ccount for this increase, there should still have been
ompensatory larger changes in the rosuvastatin-treated
roups. A second methodological explanation could be
igher visit-to-visit variability seen in all groups during the
rial, obscuring treatment group differences.
The tested rosuvastatin doses were well tolerated, as
ndicated by compliance and assessment of AEs, physical
ndings, and laboratory measurements. Muscle-related
ymptoms and CK elevations appeared to be associated with
hysical activity, because in all cases in which information
n exercise was available, the findings were preceded by
trenuous or unusual physical activity. These observations
re consistent with data in adults (18,19). Overall, the safety
rofile of rosuvastatin in this study was similar to that of
lacebo and of other statins investigated in children (6).
hase forysi Population, n  176)oubl -Blind Phase for
(Safety Analysis Population, n  176)
Rosuvastatin
n  42) 10 mg (n  44) 20 mg (n  44)
9, 25.5) 21 (18, 25) 21 (18, 23)
2, 5) 1 (1, 4) 1 (2, 5)
2, 18) 14 (11, 18) 13 (12, 17)
1, 5) 4 (1, 8) 3 (0, 7)
5, 142) 120 (78, 148) 106 (73, 170)
37, 22) 6 (16, 38) 7 (22, 26)
9) 144 (25) 139 (24)
7) 1.6 (17) 0.0 (14)
.04) 0.06 (0.04) 0.07 (0.04)
.03) 0.00 (0.04) 0.00 (0.03)
creatine kinase; GFR  glomerular filtration rate; P:C  protein/lind PAnalof D
P:C
5 mg (
21 (1
1 (
15 (1
2 (
103 (7
1.5 (
149 (2
0.0 (1
0.06 (0
0.01 (0evertheless, the study was of limited size and duration, and
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Rosuvastatin Therapy for Children With FH March 16, 2010:1121–6uture studies should focus on long-term safety and the
xistence of more rare or subtle AEs.
The decrease in compliance from 90% in the placebo-
ontrolled period to 60% in the open-label phase did not
eem to be related to the occurrence of AEs, and under-
cores the challenges of long-term medication compliance,
articularly by adolescents.
The rationale behind early and aggressive initiation of
DL-Clowering treatment in FH patients is to retard
rogression of atherosclerosis, thereby decreasing cardiovas-
ular events in later life. A placebo-controlled trial to
efinitively prove that statin therapy in children with FH
educes cardiovascular events would be unethical, given
heir known risk of early CVD if left untreated (20).
herefore, guidelines are based on expert opinion, pediatric
rials using surrogate markers for atherosclerosis, and car-
iovascular end point trials involving high-risk adults. In
hildren, trials have shown that pravastatin attenuates ath-
rosclerotic progression and moderately reduces LDL-C in
hildren with FH (3,4,7). Although it is likely that greater
DL-C lowering in children would lead to greater reduc-
ions in atherosclerotic events, just as in adults (21), neither
arly treatment nor LDL-C goal attainment per se has been
hown to reduce atherosclerotic progression using surrogate
arkers, let alone subsequent CVD events in pediatric
opulations.
This trial, along with other studies in nearly 1,000
ediatric patients, confirms that LDL-C lowering with
tatins is well tolerated in adolescents with FH and, despite
ignificant LDL-C reductions, highlights the difficulty in
chieving optimal goals in these patients.
eprint requests and correspondence: Dr. Evan A. Stein, Met-
bolic and Atherosclerosis Research Center, 4685 Forest Avenue,
incinnati, Ohio 45212. E-mail: esteinmrl@aol.com.
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